Item 5.07 Submission of Matters to a Vote of Security Holders.

On March 1, 2023, Myovant Sciences Ltd., a Bermuda exempted company limited by shares (the "Company"), held a special general meeting of shareholders (the "Special General Meeting") to vote on the proposals described in the Company's definitive proxy statement filed with the U.S. Securities and Exchange Commission on January 23, 2023. A total of 97,235,316 common shares of the Company were entitled to vote at the close of business on January 20, 2023, the record date for the Special General Meeting. 84,651,059 of the Company's common shares issued and outstanding were present or represented by proxy at the Special General Meeting, representing approximately 87.05% of those shares entitled to vote, which constituted a quorum.

Each of the proposals upon which the Company's shareholders voted at the Special General Meeting, and the final, certified results reported by the Company's independent inspector of elections, American Election Services, LLC, are set forth below.

1. The adoption and approval of the Agreement and Plan of Merger, dated as of

October 23, 2022 (as it may be amended from time to time in accordance with
    its terms, the "Merger Agreement"), and a related Statutory Merger Agreement
    (the "Statutory Merger Agreement"), by and among the Company, Sumitovant
    Biopharma Ltd. ("Sumitovant"), Zeus Sciences Ltd. and, solely with respect to
    Article IX and Annex A of the Merger Agreement, Sumitomo Pharma Co., Ltd., and
    the transactions contemplated by the Merger Agreement and the Statutory Merger
    Agreement, including a merger, pursuant to which Zeus Sciences Ltd. will merge
    with and into the Company (the "Merger"), with Myovant continuing as the
    surviving company following the Merger as a wholly owned subsidiary of
    Sumitovant (the "Merger Proposal").

The voting results of the holders of the issued and outstanding common shares of the Company entitled to vote on the Merger Proposal and voting at the Special General Meeting are as follows:



   For      Against  Abstain Broker Non-Votes
82,347,584 2,259,136 44,339         -

The voting results of the holders of the issued and outstanding common shares of the Company held by the Company's shareholders other than Sumitovant or its affiliates are as follows:



   For      Against  Abstain Broker Non-Votes
32,306,403 2,259,136 44,339         -

The Merger Proposal was approved, receiving the affirmative vote of (i) approximately 97.32% of the Company common shares issued and outstanding and entitled to vote on the Merger Proposal and voting at the Special General Meeting (such vote, the "General Shareholder Approval") and (ii) approximately 68.45% of Company common shares issued and outstanding held by the Company's shareholders other than Sumitovant or its affiliates (such vote, the "Minority Shareholder Approval" and together with the General Shareholder Approval, the "Required Shareholder Approval").



                                       2

--------------------------------------------------------------------------------

2. A non-binding, advisory proposal to approve specified compensation that may


    become payable to the Company's named executive officers in connection with
    the completion of the Merger.



   For      Against   Abstain Broker Non-Votes
74,048,487 10,234,450 368,122        -

This proposal was approved, receiving the affirmative vote of approximately 87.85% of the Company common shares issued and outstanding and entitled to vote on such proposal and voting at the Special General Meeting.

3. In connection with the Special General Meeting, the Company also solicited


    proxies with respect to a proposal to adjourn the Special General Meeting, if
    necessary or appropriate, to solicit additional proxies if there are
    insufficient votes at the time of the Special General Meeting to approve the
    Merger Proposal (the "Adjournment Proposal"). Because the Required Shareholder
    Approval was obtained for the Merger Proposal, as noted above, the Adjournment
    Proposal was rendered moot and not presented.

Now that the Company's shareholders have approved the Merger Proposal, the Company expects closing of the Merger to occur within seven business days of the date hereof, subject to satisfaction of all other conditions to closing.



                                       3

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses